DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 59.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,951 shares of the medical device company’s stock after selling 2,887 shares during the quarter. Banque Cantonale Vaudoise’s holdings in DexCom were worth $270,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Capital Research Global Investors boosted its holdings in DexCom by 21.4% in the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC boosted its holdings in shares of DexCom by 10.2% in the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after acquiring an additional 1,398,136 shares during the period. Capital World Investors boosted its holdings in shares of DexCom by 130.7% in the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after acquiring an additional 5,256,092 shares during the period. Artisan Partners Limited Partnership boosted its holdings in shares of DexCom by 164.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after acquiring an additional 3,672,471 shares during the period. Finally, Norges Bank acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $540,178,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Up 0.5 %

NASDAQ:DXCM opened at $116.64 on Monday. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The stock has a market capitalization of $46.39 billion, a price-to-earnings ratio of 75.25, a PEG ratio of 2.84 and a beta of 1.22. The stock has a fifty day moving average price of $125.29 and a two-hundred day moving average price of $125.96. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. As a group, sell-side analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Redburn Atlantic assumed coverage on DexCom in a report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price objective for the company. Citigroup increased their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Canaccord Genuity Group increased their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Finally, Raymond James increased their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $140.94.

Insider Activity

In other news, EVP Michael Jon Brown sold 2,624 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the transaction, the executive vice president now owns 68,682 shares in the company, valued at $9,618,227.28. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Kevin R. Sayer sold 49,633 shares of the stock in a transaction on Monday, April 8th. The stock was sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the sale, the chief executive officer now owns 283,893 shares of the company’s stock, valued at $39,262,401.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 2,624 shares of the stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total value of $367,464.96. Following the sale, the executive vice president now directly owns 68,682 shares in the company, valued at approximately $9,618,227.28. The disclosure for this sale can be found here. Insiders sold a total of 57,700 shares of company stock worth $7,911,495 over the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.